Use of Oxycodone in Bariatric Surgery

• Status: Not yet recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: All

Summary

There is still no effective treatment for surgical pain, especially visceral pain in bariatric surgery. Oxycodone has great application prospect in patients with obesity, but there are few clinical studies and analgesic effect is still unclear, especially in combination with esketamine.

This study was a prospective, single-center, randomized, controlled, double-blind clinical trial to compare the efficacy and safety of intravenous oxycodone and combined use of esketamine for perioperative multimodel analgesia during bariatric surgery, and the effect of esketamine on inflammatory factors.

This study was based on the hypothesis that oxycodone and the combination use with esketamine can effectively reduce the level of postoperative pain and inflammatory factors, and does not increase perioperative adverse reactions in bariatric surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qiang Fu
• Treatments: Dezocine; Esketamine; Oxycodone

Criteria

Inclusion Criteria:

• Body mass index (BMI) ≥30kg/m2;

• Laparoscopic sleeve gastrectomy (LSG) was performed;

• American Society of Anesthesiologists (ASA) Grade I to II, age: 18-50;

• Patient-controlled intravenous analgesia (PCIA) was approved.

Exclusion Criteria:

• Do not agree to sign informed consent or cannot sign for other reasons;

• Oxycodone contraindications;

• Patients with contraindications to esketamine;

• Disocine contraindications;

• Preoperative history of opioid allergy and abuse;

• Have a long history of alcoholism;

• A history of surgery or anesthesia recently;

• Changes in standard anesthesia procedures for any reason.